
|Videos|August 17, 2017
Dr. Slovin on Approaches of Immunotherapy in Prostate Cancer
Author(s)Susan F. Slovin, MD, PhD
Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses approaches of immunotherapy for patients with prostate cancer.
Advertisement
Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses approaches of immunotherapy for patients with prostate cancer.
It’s important to recognize that immunotherapy encompasses more than checkpoint inhibitors, explains Slovin. There is a wide variety of other approaches that fall under the category of immunotherapy, such as antibodies, chimeric antigen receptor T cells, and DNA vaccines.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5




































